Drug
Vepdegestrant
Vepdegestrant: highest development phase Phase 3, developed by Arvinas, Pfizer. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Arvinas, Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vepdegestrant (ARV-471/PF-07850327) NCT05909397 | Phase 3 | Breast Cancer |
| vepdegestrant NCT06125522 | Phase 1/2 | Breast Cancer |
| Vepdegestrant NCT04072952 | Phase 1/2 | Breast Cancer |
| vepdegestrant NCT06206837 | Phase 1/2 | Breast Cancer |
| vepdegestrant NCT05538312 | Phase 1 | Healthy |
| vepdegestrant NCT06275841 | Phase 1 | Healthy |
| Vepdegestrant NCT06005688 | Phase 1 | Healthy Participants |
| vepdegestrant NCT07231991 | Phase 1 | Healthy Participants |
| vepdegestrant NCT05463952 | Phase 1 | Breast Neoplasms |
| Vepdegestrant (Reference) NCT06911788 | Phase 1 |
Latest
No recent events.
Follow Vepdegestrant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.